Accessibility Menu
Yd Bio logo

Yd Bio(NASDAQ) YDES

Market Cap$158.66MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-78%
5 Year-78%
1 Year-81%
1 Month-15%
$2.28
+11.77%
+0.24Today
Yd Bio last closing stock price
MetricPriceDate
Last closeUSD 2.242026-07-24
Yd Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8.57%USD 2.452026-07-17
1 month-14.83%USD 2.632026-06-24
3 month-58.97%USD 5.462026-04-24
Year to date-81.62%USD 12.192025-12-31
1 year-81.41%USD 12.052025-07-24
3 year-80.44%USD 11.452023-07-25
5 year-77.62%USD 10.012021-07-23
Since inception-78.46%USD 10.402020-12-23

Yd Bio Financials at a Glance

Market Cap

$158.66MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$2.97M

EPS (TTM)

-$0.99

P/E Ratio

-2.27

Dividend

$0.00

Beta (Volatility)

0.10 (Low)

Price

$2.28

Volume

1

Open

$2.24

Previous Close

$2.28

Daily Range

$2.22 - $2.29

52-Week Range

$1.70 - $25.00

Estimated Earnings Date

N/A

YDES News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Yd Bio

YD Bio Limited is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm focuses on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, aiming to revolutionize treatment options for diseases with significant unmet medical needs.

Products and Services
  • Medical diagnostics for cancer prevention
  • Exosome-based therapeutics
  • Innovative solutions for unmet medical needs
Growth Outlook
  • Strong focus on cancer diagnostics and therapeutics positions the company for future growth
  • Recent investments in research and development enhance product pipeline potential
  • Market demand for innovative biopharmaceutical solutions continues to rise
Financial Highlights
  • Trailing twelve months (TTM) revenue remains at zero, indicating early-stage development
  • Net income for Q2 2025 reported at -$2,214,684, reflecting ongoing investment in R&D
  • Cash and cash equivalents stood at $6,312 as of Q2 2025, supporting operational needs
YD Bio Limited operates in the biotechnology sector, focusing on innovative solutions that address critical healthcare challenges. The company's commitment to developing advanced medical diagnostics and therapeutics positions it well within a growing market. Despite reporting no revenue in recent quarters, the emphasis on research and development suggests a strategic approach to building a robust product pipeline. The financial data indicates a significant investment in future growth, with a focus on addressing unmet medical needs in cancer treatment. As the healthcare landscape evolves, YD Bio Limited's initiatives may attract attention from investors looking for opportunities in the biopharmaceutical space.
AI Generated • Jul 21, 2026

Industry

Biotechnology

Sector

Health Care

Employees

4

CEO

Ethan Shen, PhD, EMBA

Website

www.ydesgroup.com

Headquarters

Taipei, TP 115001, TW

YDES Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

52.09%

Return on Capital

N/A

Return on Assets

-40.51%

Earnings Yield

-44.05%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$158.66MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

70.83M

Volume

1

Avg. Volume

128.53K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$1.38M

EBITDA

-$2.99M

Operating Cash Flow

-$1.18M

Capital Expenditure

-$3.00

Free Cash Flow

-$1.18M

Cash & ST Invst.

$6.01M

Total Debt

$6.76K

Yd Bio Performance Analysis

Yd Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 510,360N/A
20252025-12-31USD 596,81716.9%
Yd Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q12025-03-31N/A
Q22025-06-30N/A
Q42025-12-31N/A
Yd Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.41-31.5%
20232023-12-31USD -0.58N/A
20242024-12-31USD -0.02-96.2%
20252025-12-31USD -0.12471.6%
Yd Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-81.5%
Q12025-03-31-1080.0%
Q22025-06-3033.7%
Q42025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$158.66MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$10.58M

N/A

Employees

15

N/A

Net Income

-$2.21M

-112.9%

EBITDA

-$2.22M

-113.0%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

$6.01M

+300380650.0%

Total Debt

$6.76K

N/A

Accounts Receivable

$712.26K

+1221.3%

Inventory

$1.88M

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$6.76K

N/A

Return on Assets

-40.51%

N/A

Return on Invested Capital

-6.12%

N/A

Free Cash Flow

-$298.19K

+49.7%

Operating Cash Flow

-$298.19K

+49.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LENZLENZ Therapeutics, Inc.
$5.70+4.01%
PRMEPrime Medicine, Inc.
$3.01+2.03%
TBPHTheravance Biopharma Inc
$16.86+0.00%
BTXBlackRock Innovation and Growth Term Trust
$8.04-1.95%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%
TAT&T
$24.42+0.01%

Questions About YDES

What is the current price of Yd Bio?

Yd Bio is trading at $2.28 per share.

What is the 52-week range for Yd Bio?

Over the past 52 weeks, Yd Bio has traded between $1.70 and $25.00.

How much debt does Yd Bio have?

As of the most recent reporting period, Yd Bio reported total debt of $0.00.

How much cash does Yd Bio have on hand?

Yd Bio reported $6.31K in cash and cash equivalents in its most recent financial results.

What is Yd Bio’s dividend yield?

Yd Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services